>

Daniel ODay - Gilead Sciences Chairman of the Board, CEO

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>GIL</div>
GILD -- USA Stock  

Trending

  Chairman
Mr. Daniel ODay is appointed as Chairman of the Board, Chief Executive Officer of the company. Mr. ODay joined Gilead as Chairman and Chief Executive Officer on March 1, 2019. Prior to Gilead, Mr. ODay served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the companys pharmaceutical and diagnostics divisions in North America, Europe and Asia. During his time at Roche, Mr. ODay demonstrated vision and leadership, helping to engineer the acquisitions of Flatiron Health and Foundation Medicine in 2018. He served as a member of Roches Corporationrationrate Executive Committee, as well as on a number of public and private boards, including Genentech, Inc
Age: 54  Chairman Since 2019  MBA    
650 574-3000  www.gilead.com
O?Day holds a bachelor?s degree in biology from Georgetown University and an MBA from Columbia University in New York.

Management Efficiency

The company currently holds 28.84 B in liabilities with Debt to Equity (D/E) ratio of 139.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has Current Ratio of 3.0 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Kenneth FrazierMerck Company
2011
Thibaut MongonJohnson Johnson
2018
Lamberto AndreottiBristol Myers Squibb Company
2015
Joaquin DuatoJohnson Johnson
2018
Alex GorskyJohnson Johnson
2012
Giovanni CaforioBristol Myers Squibb Company
2017
Enrico VanniNovartis AG
2013
Jorge MesquitaJohnson Johnson
2016
Alex KrauerNovartis AG
N/A
John LechleiterEli Lilly And Company
2016
Jennifer TaubertJohnson Johnson
2018
Ashley McEvoyJohnson Johnson
2018
Paul BisaroAllergan Plc
2016
Moncef SlaouiGlaxoSmithKline PLC
2014
Joerg ReinhardtNovartis AG
2013
Brenton SaundersAllergan Plc
2016
Leif JohanssonAstrazeneca PLC
2012
Paulus StoffelsJohnson Johnson
2018
Sandra PetersonJohnson Johnson
2017
Ian ReadPfizer
2018
Ulrich LehnerNovartis AG
2006

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human ResourcesView
John McHutchison, Executive Vice President - Clinical ResearchView
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development OperationsView
John Martin, Chairman and CEOView
Andrew Dickinson, Executive Vice President - Corporate Development and StrategyView
Gayle Wilson, Independent DirectorView
Daniel ODay, Chairman of the Board, CEOView
Jacqueline Barton, DirectorView
Brett Pletcher, Executive VP and General CounselView
William Lee, Executive Vice President - ResearchView
John Madigan, Independent DirectorView
Martin Silverstein, Executive Vice President - StrategyView
Kevin Lofton, Independent DirectorView
Paul Carter, Executive Vice President - Commercial OperationsView
Gregg Alton, Executive VP of Corporate and Medical Affairs and SecretaryView
Diana Brainard, Senior Vice President HIV and Emerging Viral InfectionsView
Carla Hills, Independent DirectorView
John Cogan, Lead Independent DirectorView
John Milligan, Pres and COOView
Nicholas Moore, Independent DirectorView
James Meyers, Executive Vice President - Worldwide Commercial OperationsView
Katie Watson, Executive Vice President of Human ResourcesView
Kelly Kramer, DirectorView
Johanna Mercier, Chief Commercial OfficerView
Jyoti Mehra, Executive Vice President of Human ResourcesView
Laura Hamill, Executive Vice President - Worldwide Commercial OperationsView
Robin Washington, CFO and Executive VPView
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandDView
Per WoldOlsen, Independent DirectorView
Harish Manwani, DirectorView
Taiyin Yang, Executive Vice President - Pharmaceutical Development and ManufacturingView
Kevin Young, COOView
Etienne Davignon, Independent DirectorView
Richard Whitley, Independent DirectorView

Stock Performance Indicators

Did you try this?

Run Price Ceiling Movement Now

   

Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.